|Access to Drugs (UNAIDS, 1998, 12 p.)|
Chaudhury R (ed). International experience in rational use of drugs (vol. 2.) Bangkok: College of Public Health, Chulalongkorn University. Articles collected under auspices of UNESCO, including discussion of essential drug programmes in India, Myanmar, Thailand, Zimbabwe.
Dormont PJ (ed). Prise en charge des personnes atteintes par le VIH, 1996 edition. Paris: Flammarion, 1996. Practical, comprehensive guide to management of HIV. Published with support of Ministry of Labour and Social Services, and widely distributed to physicians in France.
Essential Drugs: WHO Model List, in WHO Drug Information, 12(1), 1998.
Hardon A, Van der Geest S, Geerling H & Le Grand A. The provision and use of drugs in developing countries. Review of studies and annotated bibliography. Amsterdam: Het Spinhuis Publishers, 1991. Overview (163 pages) of availability and rational use of drugs by region and country. Analysis of obstacles, research gaps, recommendations.
International conference on national medicinal drug policies: the way forward (conference proceedings). Supplement to Australian Prescriber, 1997; 20. Examples of drug policies around the world, including access to medicines and rational use of drugs. 272 pages.
Management Sciences for Health. International Drug Price Indicator Guide. Boston: Management Sciences for Health, 1996. Updated annually, with text in English, French, Spanish. Drugs are sorted alphabetically and by therapeutic category.
Management Sciences for Health. Managing Drug Supply: The Selection, Procurement, Distribution, and Use of Pharmaceuticals (2nd edition). Boston: Kumarian Press, 1998. Comprehensive manual with practical case studies on all aspects of drug selection, procurement, distribution and use.
Nine Guidance Modules on Anti-retroviral Treatments. Geneva: WHO, 1998. Also available on the Internet at http://www.who.ch/ asd/arv/index.htm
Steward GJ (ed). Managing HIV. Sydney: The Australasian Medical Publishing Company, 1996. Complete 208-page overview of HIV medicine and clinical practice, written for primary care doctors with the information needed to work with specialists.
Anon. The importance of pharmaceuticals and essential drugs programs. In: Better health in Africa: experience and lessons learned. Washington DC: The World Bank, 1994. pp 67 - 84. Suggests that drugs needed to treat 85% of common illnesses, including expanded treatment of STDs, could be covered by annual per capita cost of US$ 1.60 - less than current spending by some African countries. Since drug coverage is reduced by inefficiences and waste, management should be a government priority.
Van Praag E, Fernyak S, Katz AM (eds). The Implications of antiretroviral treatments. Geneva: WHO, 1997. Conclusions of informal consultation held to discuss latest antiretroviral therapies and aspects of their use, cost, and long-term effectiveness.
WHO. Health reform and drug financing. Geneva: WHO, 1998. WHO/DAP/98.3. Overview of major sources of drug financing: public financing, drug insurance, user charges, voluntary and local financing, donor financing and drug donations, and development loans. Also discusses affordability for consumers and cost control.
© Joint United Nations Programme on HIV/AIDS 1998. All rights reserved. This publication may be freely reviewed, quoted, reproduced or translated, in part or in full, provided the source is acknowledged. It may not be sold or used in conjunction with commercial purposes without prior written approval from UNAIDS (contact: UNAIDS Information Centre, Geneva - see page 2.). The views expressed in documents by named authors are solely the responsibility of those authors. The designations employed and the presentation of the material in this work do not imply the expression of any opinion whatsoever on the part of UNAIDS concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers and boundaries. The mention of specific companies or of certain manufacturers' products do not imply that they are endorsed or recommended by UNAIDS in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.